<ul>
<li>德康医疗股票：财报超预期和新市场准入推动看涨预期</li>
</ul>
<p>德康医疗公司（NASDAQ:DXCM - 免费报告）- 股票分析师在 7 月 30 日星期三发布的报告中，上调了德康医疗 2028 财年的每股收益（EPS）预期。Leerink Partnrs 的分析师 M. Kratky 现在预计该医疗设备公司将实现每股收益 3.83 美元，高于之前的 3.82 美元预期。德康医疗当前全年的共识预期为每股收益 2.03 美元。Leerink Partnrs 还对德康医疗 2029 财年的收益预期为每股 4.41 美元。</p>
<p>德康医疗（NASDAQ:DXCM - 获取免费报告）最近在 7 月 30 日星期三公布了季度财报。该医疗设备公司报告季度每股收益（EPS）为 0.48 美元，超出市场共识预期的 0.45 美元，超出幅度为 0.03 美元。德康医疗的股本回报率为 32.05%，净利润率为 13.29%。该公司在本季度的收入为 11.6 亿美元，而市场共识预期为 11.3 亿美元。在去年同期，该公司每股收益为 0.43 美元。与去年同期相比，该公司的季度收入增长了 15.2%。</p>
<ul>
<li>3 只新 ETF 在投资者中获得早期关注</li>
</ul>
<p>DXCM 的股票还受到其他几份报告的关注。巴克莱将德康医疗的目标价从 93.00 美元上调至 98.00 美元，并在周三的报告中给予该股票 “持平” 评级。华尔街 Zen 在 7 月 18 日星期五将德康医疗的评级从 “持有” 上调至 “买入”。派珀·桑德勒在周四的报告中将德康医疗的目标价从 90.00 美元上调至 100.00 美元，并给予该股票 “超配” 评级。Truist Financial 在 6 月 16 日星期一开始对德康医疗进行覆盖，给予 “买入” 评级和 102.00 美元的目标价。最后，瑞穗将德康医疗的目标价从 95.00 美元上调至 100.00 美元，并在 7 月 16 日的报告中给予该股票 “跑赢大盘” 评级。四位投资分析师对该股票给予 “持有” 评级，十六位给予 “买入” 评级，两位给予 “强烈买入” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 99.89 美元。</p>
<p><strong>获取我们对德康医疗的最新分析</strong></p>
<h2>德康医疗股票下跌 9.3%</h2>
<ul>
<li>关注的三只股票：期权交易者押注大幅上涨</li>
</ul>
<p>德康医疗的股票在星期五开盘价为 80.77 美元。德康医疗的 1 年最低价为 57.52 美元，1 年最高价为 93.25 美元。该公司的 50 日移动平均线为 84.67 美元，200 日移动平均线为 80.62 美元。公司的市值为 316.7 亿美元，市盈率为 56.09，市盈增长比率为 1.90，贝塔值为 1.44。公司的债务与股本比率为 0.55，流动比率为 1.50，速动比率为 1.32。</p>
<h2>机构资金流入和流出</h2>
<p>最近几位大型投资者买入和卖出了 DXCM 的股票。Horizon Investments LLC 在第一季度增持了德康医疗的股份，增幅为 2.2%。Horizon Investments LLC 现在拥有德康医疗的 5608 股股票，价值 383,000 美元，在此期间又增持了 123 股。Nia Impact Advisors LLC 在第四季度增持了德康医疗的股份，增幅为 1.4%。Nia Impact Advisors LLC 现在拥有德康医疗的 9850 股股票，价值 766,000 美元，在此期间又增持了 140 股。Covestor Ltd 在第四季度增持了德康医疗的股份，增幅为 15.6%。Covestor Ltd 现在拥有德康医疗的 1109 股股票，价值 86,000 美元，在此期间又增持了 150 股。Wedbush Securities Inc.在第一季度增持了德康医疗的股份，增幅为 1.2%。Wedbush Securities Inc.现在拥有德康医疗的 13168 股股票，价值 899,000 美元，在上个季度又购买了 157 股。最后，Argonautica Private Wealth Management Inc.在第一季度增持了德康医疗的股份，增幅为 3.2%。Argonautica Private Wealth Management Inc.现在拥有德康医疗的 5958 股股票，价值 407,000 美元，在上个季度又购买了 182 股。97.75% 的股票由机构投资者和对冲基金持有。</p>
<h2>内部人员买卖</h2>
<p>在相关消息中，董事 Nicholas Augustinos 在 6 月 16 日星期一出售了 3672 股股票，交易价格为每股 82.80 美元，总交易额为 304,041.60 美元。交易完成后，该董事直接持有公司 33411 股股票，价值约为 2,766,430.80 美元。这代表其持股比例减少了 9.90%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，执行副总裁 Michael Jon Brown 在 5 月 23 日星期五出售了 10,000 股股票，交易价格为每股 84.28 美元，总价值为 842,800.00 美元。交易完成后，该执行副总裁直接持有公司 95602 股股票，价值 8,057,336.56 美元。该交易代表其持股比例减少了 9.47%。该交易的披露信息可在此处找到。在过去三个月中，内部人员出售了 28656 股公司股票，价值 2,412,191 美元。当前公司内部人员持有的股票占比为 0.32%。</p>
<h2>关于德康医疗</h2>
<p>（获取免费报告）</p>
<p>德康医疗公司是一家医疗设备公司，专注于在美国及国际市场设计、开发和商业化连续血糖监测（CGM）系统。该公司为糖尿病患者及医疗服务提供者提供其系统。其产品包括 Dexcom G6 和 Dexcom G7，这些是用于糖尿病管理的集成 CGM 系统；Dexcom Share，一个远程监测系统；Dexcom Real-Time API，允许授权的第三方软件开发者将实时 CGM 数据集成到他们的数字健康应用和设备中；以及 Dexcom ONE，旨在替代指尖血糖测试以进行糖尿病治疗决策。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过德康医疗</li>
<li>现在值得购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>Newmont 的财务实力为黄金矿业设定了高标准</li>
<li>投资旅游股票的好处</li>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
<li>成长股：它们是什么，例子以及如何投资</li>
<li>大幅超预期，更大的计划：AEP 股票因数据中心繁荣而上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在德康医疗吗？</h2>
<p>在你考虑德康医疗之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而德康医疗并不在名单上。</p>
<p>虽然德康医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

德康医疗

<p>Leerink Partners 将 DexCom, Inc. 的 2028 财年每股收益（EPS）预期上调至 3.83 美元，较之前的 3.82 美元有所增加。目前全年每股收益的共识预期为 2.03 美元。DexCom 上个季度报告的每股收益为 0.48 美元，超出预期。分析师对 DexCom 的共识评级为 “适度买入”，目标价为 99.89 美元。该股票开盘价为 80.77 美元，市值为 316.7 亿美元，市盈率为 56.09。机构投资者持有该股票的 97.75%</p>

<ul>
<li>DexCom Stock: Earnings Beat and New Market Access Drive Bull Case</li>
</ul>
<div class="lb-trans"><ul>
<li>德康医疗股票：财报超预期和新市场准入推动看涨预期</li>
</ul>
</div><p>DexCom, Inc. (NASDAQ:DXCM - Free Report) - Stock analysts at Leerink Partnrs raised their FY2028 earnings per share (EPS) estimates for DexCom in a report released on Wednesday, July 30th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will earn $3.83 per share for the year, up from their previous estimate of $3.82. The consensus estimate for DexCom's current full-year earnings is $2.03 per share. Leerink Partnrs also issued estimates for DexCom's FY2029 earnings at $4.41 EPS.</p>
<div class="lb-trans"><p>德康医疗公司（NASDAQ:DXCM - 免费报告）- 股票分析师在 7 月 30 日星期三发布的报告中，上调了德康医疗 2028 财年的每股收益（EPS）预期。Leerink Partnrs 的分析师 M. Kratky 现在预计该医疗设备公司将实现每股收益 3.83 美元，高于之前的 3.82 美元预期。德康医疗当前全年的共识预期为每股收益 2.03 美元。Leerink Partnrs 还对德康医疗 2029 财年的收益预期为每股 4.41 美元。</p>
</div><p>DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 32.05% and a net margin of 13.29%. The company had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the company earned $0.43 earnings per share. The company's revenue for the quarter was up 15.2% compared to the same quarter last year.</p>
<div class="lb-trans"><p>德康医疗（NASDAQ:DXCM - 获取免费报告）最近在 7 月 30 日星期三公布了季度财报。该医疗设备公司报告季度每股收益（EPS）为 0.48 美元，超出市场共识预期的 0.45 美元，超出幅度为 0.03 美元。德康医疗的股本回报率为 32.05%，净利润率为 13.29%。该公司在本季度的收入为 11.6 亿美元，而市场共识预期为 11.3 亿美元。在去年同期，该公司每股收益为 0.43 美元。与去年同期相比，该公司的季度收入增长了 15.2%。</p>
</div><ul>
<li>3 New ETFs Finding Early Traction With Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只新 ETF 在投资者中获得早期关注</li>
</ul>
</div><p>DXCM has been the subject of several other reports. Barclays increased their price target on DexCom from $93.00 to $98.00 and gave the stock an &#34;equal weight&#34; rating in a report on Wednesday. Wall Street Zen upgraded DexCom from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Friday, July 18th. Piper Sandler increased their price target on DexCom from $90.00 to $100.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday. Truist Financial started coverage on DexCom in a report on Monday, June 16th. They issued a &#34;buy&#34; rating and a $102.00 price target for the company. Finally, Mizuho increased their price target on DexCom from $95.00 to $100.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, July 16th. Four investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $99.89.</p>
<div class="lb-trans"><p>DXCM 的股票还受到其他几份报告的关注。巴克莱将德康医疗的目标价从 93.00 美元上调至 98.00 美元，并在周三的报告中给予该股票 “持平” 评级。华尔街 Zen 在 7 月 18 日星期五将德康医疗的评级从 “持有” 上调至 “买入”。派珀·桑德勒在周四的报告中将德康医疗的目标价从 90.00 美元上调至 100.00 美元，并给予该股票 “超配” 评级。Truist Financial 在 6 月 16 日星期一开始对德康医疗进行覆盖，给予 “买入” 评级和 102.00 美元的目标价。最后，瑞穗将德康医疗的目标价从 95.00 美元上调至 100.00 美元，并在 7 月 16 日的报告中给予该股票 “跑赢大盘” 评级。四位投资分析师对该股票给予 “持有” 评级，十六位给予 “买入” 评级，两位给予 “强烈买入” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 99.89 美元。</p>
</div><p><strong>Get Our Latest Analysis on DexCom</strong></p>
<div class="lb-trans"><p><strong>获取我们对德康医疗的最新分析</strong></p>
</div><h2>DexCom Stock Down 9.3%</h2>
<div class="lb-trans"><h2>德康医疗股票下跌 9.3%</h2>
</div><ul>
<li>Top 3 Stocks to Watch: Options Traders Bet on Big Gains</li>
</ul>
<div class="lb-trans"><ul>
<li>关注的三只股票：期权交易者押注大幅上涨</li>
</ul>
</div><p>Shares of DexCom stock opened at $80.77 on Friday. DexCom has a 1 year low of $57.52 and a 1 year high of $93.25. The business has a 50-day moving average of $84.67 and a two-hundred day moving average of $80.62. The company has a market capitalization of $31.67 billion, a P/E ratio of 56.09, a price-to-earnings-growth ratio of 1.90 and a beta of 1.44. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.50 and a quick ratio of 1.32.</p>
<div class="lb-trans"><p>德康医疗的股票在星期五开盘价为 80.77 美元。德康医疗的 1 年最低价为 57.52 美元，1 年最高价为 93.25 美元。该公司的 50 日移动平均线为 84.67 美元，200 日移动平均线为 80.62 美元。公司的市值为 316.7 亿美元，市盈率为 56.09，市盈增长比率为 1.90，贝塔值为 1.44。公司的债务与股本比率为 0.55，流动比率为 1.50，速动比率为 1.32。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently bought and sold shares of DXCM. Horizon Investments LLC boosted its stake in shares of DexCom by 2.2% during the 1st quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after acquiring an additional 123 shares during the period. Nia Impact Advisors LLC boosted its stake in shares of DexCom by 1.4% during the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after acquiring an additional 140 shares during the period. Covestor Ltd boosted its stake in shares of DexCom by 15.6% during the 4th quarter. Covestor Ltd now owns 1,109 shares of the medical device company's stock worth $86,000 after acquiring an additional 150 shares during the period. Wedbush Securities Inc. lifted its holdings in DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after purchasing an additional 157 shares during the last quarter. Finally, Argonautica Private Wealth Management Inc. lifted its holdings in DexCom by 3.2% during the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock worth $407,000 after purchasing an additional 182 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>最近几位大型投资者买入和卖出了 DXCM 的股票。Horizon Investments LLC 在第一季度增持了德康医疗的股份，增幅为 2.2%。Horizon Investments LLC 现在拥有德康医疗的 5608 股股票，价值 383,000 美元，在此期间又增持了 123 股。Nia Impact Advisors LLC 在第四季度增持了德康医疗的股份，增幅为 1.4%。Nia Impact Advisors LLC 现在拥有德康医疗的 9850 股股票，价值 766,000 美元，在此期间又增持了 140 股。Covestor Ltd 在第四季度增持了德康医疗的股份，增幅为 15.6%。Covestor Ltd 现在拥有德康医疗的 1109 股股票，价值 86,000 美元，在此期间又增持了 150 股。Wedbush Securities Inc.在第一季度增持了德康医疗的股份，增幅为 1.2%。Wedbush Securities Inc.现在拥有德康医疗的 13168 股股票，价值 899,000 美元，在上个季度又购买了 157 股。最后，Argonautica Private Wealth Management Inc.在第一季度增持了德康医疗的股份，增幅为 3.2%。Argonautica Private Wealth Management Inc.现在拥有德康医疗的 5958 股股票，价值 407,000 美元，在上个季度又购买了 182 股。97.75% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员买卖</h2>
</div><p>In related news, Director Nicholas Augustinos sold 3,672 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the transaction, the director directly owned 33,411 shares of the company's stock, valued at approximately $2,766,430.80. This represents a 9.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 10,000 shares of the stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total value of $842,800.00. Following the transaction, the executive vice president directly owned 95,602 shares of the company's stock, valued at $8,057,336.56. This trade represents a 9.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,656 shares of company stock valued at $2,412,191. 0.32% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Nicholas Augustinos 在 6 月 16 日星期一出售了 3672 股股票，交易价格为每股 82.80 美元，总交易额为 304,041.60 美元。交易完成后，该董事直接持有公司 33411 股股票，价值约为 2,766,430.80 美元。这代表其持股比例减少了 9.90%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。此外，执行副总裁 Michael Jon Brown 在 5 月 23 日星期五出售了 10,000 股股票，交易价格为每股 84.28 美元，总价值为 842,800.00 美元。交易完成后，该执行副总裁直接持有公司 95602 股股票，价值 8,057,336.56 美元。该交易代表其持股比例减少了 9.47%。该交易的披露信息可在此处找到。在过去三个月中，内部人员出售了 28656 股公司股票，价值 2,412,191 美元。当前公司内部人员持有的股票占比为 0.32%。</p>
</div><h2>About DexCom</h2>
<div class="lb-trans"><h2>关于德康医疗</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.</p>
<div class="lb-trans"><p>德康医疗公司是一家医疗设备公司，专注于在美国及国际市场设计、开发和商业化连续血糖监测（CGM）系统。该公司为糖尿病患者及医疗服务提供者提供其系统。其产品包括 Dexcom G6 和 Dexcom G7，这些是用于糖尿病管理的集成 CGM 系统；Dexcom Share，一个远程监测系统；Dexcom Real-Time API，允许授权的第三方软件开发者将实时 CGM 数据集成到他们的数字健康应用和设备中；以及 Dexcom ONE，旨在替代指尖血糖测试以进行糖尿病治疗决策。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than DexCom</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>Newmont's Financial Strength Sets a High Bar for Gold Miners</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Golden Cross Alert: 3 Stocks With Serious Upside Potential</li>
<li>Growth Stocks: What They Are, Examples and How to Invest</li>
<li>Big Beat, Bigger Plans: AEP Stock Powers Up on Data Center Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过德康医疗</li>
<li>现在值得购买的 2 只金融科技股票和 1 只应避免的股票</li>
<li>Newmont 的财务实力为黄金矿业设定了高标准</li>
<li>投资旅游股票的好处</li>
<li>黄金交叉警报：3 只具有重大上涨潜力的股票</li>
<li>成长股：它们是什么，例子以及如何投资</li>
<li>大幅超预期，更大的计划：AEP 股票因数据中心繁荣而上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFhDTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=DXCM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in DexCom Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在德康医疗吗？</h2>
</div><p>Before you consider DexCom, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑德康医疗之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DexCom wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前购买的股票……而德康医疗并不在名单上。</p>
</div><p>While DexCom currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然德康医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Leerink Partners 对德康医疗 2028 财年收益的看法是积极的